Alamar Biosciences (NASDAQ:ALMR) Major Shareholder Corporate Gp Vi Ltd. Qiming Sells 147,934 Shares of Stock

Alamar Biosciences, Inc. (NASDAQ:ALMR) major shareholder Corporate Gp Vi Ltd. Qiming sold 147,934 shares of the business’s stock in a transaction that occurred on Friday, October 23rd. The shares were sold at an average price of $30.59, for a total value of $4,525,301.06. Following the completion of the sale, the insider owned 169,753 shares of the company’s stock, valued at $5,192,744.27. The trade was a 46.57% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Major shareholders that own at least 10% of a company’s stock are required to disclose their sales and purchases with the SEC.

Corporate Gp Vi Ltd. Qiming also recently made the following trade(s):

• On Monday, October 26th, Corporate Gp Vi Ltd. Qiming sold 132,524 shares of Alamar Biosciences stock. The shares were sold at an average price of $30.52, for a total value of $4,044,632.48.
• On Thursday, October 22nd, Corporate Gp Vi Ltd. Qiming sold 133,811 shares of Alamar Biosciences stock. The stock was sold at an average price of $29.33, for a total transaction of $3,924,676.63.
• On Wednesday, October 21st, Corporate Gp Vi Ltd. Qiming sold 208,815 shares of Alamar Biosciences stock. The stock was sold at an average price of $30.31, for a total transaction of $6,329,182.65.
• On Tuesday, October 20th, Corporate Gp Vi Ltd. Qiming sold 142,004 shares of Alamar Biosciences stock. The stock was sold at an average price of $27.89, for a total transaction of $3,960,491.56.
• On Monday, October 19th, Corporate Gp Vi Ltd. Qiming sold 75,508 shares of Alamar Biosciences stock. The shares were sold at an average price of $26.34, for a total transaction of $1,988,880.72.
• On Friday, October 16th, Corporate Gp Vi Ltd. Qiming sold 136 shares of Alamar Biosciences stock. The shares were sold at an average price of $27.02, for a total transaction of $3,674.72.
• On Thursday, October 15th, Corporate Gp Vi Ltd. Qiming sold 173,537 shares of Alamar Biosciences stock. The shares were sold at an average price of $27.73, for a total transaction of $4,812,181.01.

Alamar Biosciences Price Performance

ALMR traded up $1.54 during trading on Tuesday, hitting $31.93. 508,078 shares of the stock traded hands, compared to its average volume of 410,608. The company has a market cap of $2.22 billion and a price-to-earnings ratio of -16.29. Alamar Biosciences, Inc. has a 12-month low of $18.84 and a 12-month high of $39.61. The company has a debt-to-equity ratio of 0.03, a current ratio of 11.85 and a quick ratio of 10.23. The company has a 50-day moving average price of $30.79.

Alamar Biosciences (NASDAQ:ALMR) last released its quarterly earnings data on Tuesday, August 11th. The company reported ($0.22) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.36) by $0.14. The firm had revenue of $29.43 million during the quarter. As a group, equities analysts predict that Alamar Biosciences, Inc. will post -1.22 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several equities analysts have recently issued reports on the company. TD Cowen reissued a “buy” rating on shares of Alamar Biosciences in a research note on Wednesday, July 15th. Weiss Ratings lowered Alamar Biosciences from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Friday. JPMorgan Chase & Co. lifted their price target on shares of Alamar Biosciences from $32.00 to $35.00 and gave the company an “overweight” rating in a report on Tuesday, August 11th. Finally, Stifel Nicolaus boosted their price objective on shares of Alamar Biosciences from $28.00 to $32.00 and gave the company a “buy” rating in a research report on Tuesday, August 11th. Four analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $31.80.

Institutional Trading of Alamar Biosciences

Several large investors have recently bought and sold shares of ALMR. Squarepoint Ops LLC bought a new position in shares of Alamar Biosciences in the 2nd quarter worth approximately $283,000. State Street Corp purchased a new stake in Alamar Biosciences in the second quarter worth $3,930,000. Wellington Management Group LLP purchased a new stake in Alamar Biosciences in the second quarter worth $12,407,000. Finally, Braidwell LP bought a new position in Alamar Biosciences in the second quarter worth $29,365,000.

About Alamar Biosciences

Alamar Biosciences, Inc (NASDAQ: ALMR) is a life sciences company focused on advancing proteomics and enabling earlier detection, diagnosis and monitoring of disease. The company develops technologies designed to measure very low levels of proteins in biological samples, supporting research in areas such as oncology, neurology, immunology and other complex diseases.

Its primary technology is the NULISA platform, a highly sensitive, multiplexed immunoassay system that combines affinity-based protein detection with digital counting.